本文選題：慢性乙型肝炎 + 重組人干擾素αb��； 參考：《中國藥房》2017年08期

【摘要】：目的:觀察薄芝糖肽和胸腺五肽分別聯(lián)合重組人干擾素α2b治療慢性乙型肝炎的療效及安全性。方法:選擇2014年1月-2015年1月我院90例慢性乙型肝炎患者,隨機分為A、B、C組,各30例。A組患者給予注射用重組人干擾素α2b(假單胞菌)500萬IU皮下注射,qod;B組患者在A組基礎(chǔ)上加用薄芝糖肽注射液4 m L加入5%葡萄糖注射液250 m L中,ivgtt,qd;C組患者在A組基礎(chǔ)上加用注射用胸腺五肽2 mg加入5%葡萄糖注射液250 m L中,ivgtt,qd。3組患者均治療24周。比較3組患者治療4、8、12、24周丙氨酸轉(zhuǎn)氨酶(ALT)復(fù)常率、HBeAg陰轉(zhuǎn)率、HBeAg/抗HBeAg血清轉(zhuǎn)換率(以下簡稱"HBeAg轉(zhuǎn)換率")、HBV-DNA陰轉(zhuǎn)率、乙肝表面抗原(HBsAg)和HBV-DNA下降量,治療24周時的HBsAg陰轉(zhuǎn)率,并記錄不良反應(yīng)的發(fā)生情況。結(jié)果:治療4、8、12周,3組患者ALT復(fù)常率、HBeAg陰轉(zhuǎn)率、HBeAg轉(zhuǎn)換率、HBsAg下降量比較,差異均無統(tǒng)計學(xué)意義(P0.05)。治療4周,B組和C組患者HBV-DNA轉(zhuǎn)陰率顯著高于A組,C組患者HBV-DNA下降量顯著大于A組和B組,差異有統(tǒng)計學(xué)意義(P0.05)。治療8、12周,B組和C組患者HBV-DNA陰轉(zhuǎn)率和HBV-DNA下降量顯著高于A組,差異有統(tǒng)計學(xué)意義(P0.05),但B組與C組間比較,差異無統(tǒng)計學(xué)意義(P0.05)。治療24周,3組患者ALT復(fù)常率、HBeAg轉(zhuǎn)換率、HBsAg下降量及HBsAg陰轉(zhuǎn)率比較,差異均無統(tǒng)計學(xué)意義(P0.05);B組和C組患者HBeAg陰轉(zhuǎn)率、HBV-DNA陰轉(zhuǎn)率和HBV-DNA下降量顯著高于A組,差異有統(tǒng)計學(xué)意義(P0.05),但B組與C組間比較,差異無統(tǒng)計學(xué)意義(P0.05)。3組患者不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:薄芝糖肽和胸腺五肽分別聯(lián)合重組人干擾素α2b對慢性乙型肝炎具有較好的抑制病毒增殖作用,且在ALT復(fù)常率、HBeAg轉(zhuǎn)換率、HBsAg下降量及HBsAg陰轉(zhuǎn)率方面效果相當(dāng)。
[Abstract]:Aim: to observe the efficacy and safety of Ganoderma lucidum glycopeptide and thymus pentapeptide combined with recombinant human interferon 偽 2b in the treatment of chronic hepatitis B. Methods: from January 2014 to January 2015, 90 patients with chronic hepatitis B in our hospital were randomly divided into two groups. 30 patients in group A were treated with recombinant human interferon 偽 2b (Pseudomonas pseudomonas) 5 million IU subcutaneously injected subcutaneously in group B, on the basis of group A, the patients in group B were treated with 4 mL of Ganoderma lucidum injection and 250ml of 5% glucose injection. The patients in group A were treated for 24 weeks with the addition of 2 mg thymus pentapeptide for injection into 250 mL of 5% glucose injection. The HBeAg / anti-HBeAg seroconversion rate (HBeAg / anti-HBeAg seroconversion rate), HBV-DNA negative conversion rate, HBV-DNA decrease rate and HBsAg negative conversion rate at 24 weeks after treatment were compared among the three groups. Adverse reactions were recorded. Results: there was no significant difference in alt normalization rate, HBeAg negative conversion rate and HBeAg conversion rate and the decrease of HBsAg in the 3 groups after 12 weeks of treatment (P 0.05). The negative rate of HBV-DNA in group B and group C was significantly higher than that in group A and C at 4 weeks after treatment, and the decrease of HBV-DNA in group A was significantly higher than that in group A and group B. the difference was statistically significant (P 0.05). At 812 weeks, the negative rate of HBV-DNA and the decrease of HBV-DNA in group B and C were significantly higher than those in group A, and the difference was statistically significant (P 0.05), but there was no significant difference between group B and group C (P 0.05). After 24 weeks of treatment, there was no significant difference in alt normalization rate, HBeAg conversion rate, HBsAg negative conversion rate and HBsAg negative conversion rate. There was no significant difference in HBeAg negative conversion rate and HBV-DNA decrease rate between group B and group C, which were significantly higher than those in group A. The difference was statistically significant (P 0.05), but there was no significant difference between group B and group C in the incidence of adverse reactions. There was no significant difference in the incidence of adverse reactions between group B and group C, and there was no significant difference in the incidence of adverse reactions between group B and group C (P 0.05). Conclusion: Ganoderma lucidum glycopeptide and thymic pentapeptide combined with recombinant human interferon 偽 2b have a good inhibitory effect on chronic hepatitis B virus proliferation, and have the same effect on alt normalization rate and HBeAg conversion rate, decrease of HBsAg and HBsAg negative conversion rate.
【作者單位】： 濟南市傳染病醫(yī)院七科;山東省醫(yī)學(xué)科學(xué)院藥物研究所;
【分類號】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 徐俊楊;劉茲仁;;干擾素聯(lián)合胸腺五肽治療慢性乙肝療效觀察[J];深圳中西醫(yī)結(jié)合雜志;2015年17期

2 張俊霞;張丹;李麗芳;孔洪彬;趙斗貴;;重組人干擾素聯(lián)合薄芝糖肽治療高甲胎蛋白慢性乙型肝炎的臨床觀察[J];中國藥房;2015年09期

3 田洲;渠亞超;鮑旭麗;謝云;郭佳;閭軍;;胸腺五肽顯著增強干擾素在抗病毒治程中的特異性CTL效應(yīng)[J];現(xiàn)代生物醫(yī)學(xué)進展;2015年07期

4 孫仁山;陳曉紅;李文維;趙麗蓉;;薄芝糖肽的臨床應(yīng)用[J];時珍國醫(yī)國藥;2009年08期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 沈菲;梁玉記;;薄芝糖肽與胸腺五肽分別聯(lián)合重組人干擾素α2b治療HBeAg陽性的慢性乙型肝炎的臨床觀察[J];中國藥房;2017年08期

2 戴冬艷;徐力;華杰;;HPLC-ELSD法測定薄芝糖肽注射液中間體中4種游離糖成分[J];中國新藥雜志;2016年21期

3 金高娃;秦迎春;葛永利;欒巍;烏云高娃;;胸腺五肽聯(lián)合化療治療肺癌患者效果及對血清、呼氣冷凝液ET-1和血清T淋巴細(xì)胞亞群水平的影響[J];疑難病雜志;2016年09期

4 李敏;魏冬梅;馬巖;劉金輝;谷欣;;薄芝糖肽注射液對晚期腫瘤患者T淋巴細(xì)胞亞群及NK細(xì)胞增殖的影響[J];世界最新醫(yī)學(xué)信息文摘;2016年33期

5 劉曉瓊;沈宏輝;陳佳欣;柏兆方;王伽伯;肖小河;;苦參堿類生物堿聯(lián)合胸腺肽抗HBV作用研究[J];中國中藥雜志;2016年07期

6 崔佳;李明;蔣丹陽;馬丹華;王新敏;吳莉;;薄芝糖肽注射劑不良反應(yīng)報告綜合分析[J];中國處方藥;2015年12期

7 孫宇;鄒燕鵬;尹寶嬌;張樹平;盛潔;錢鵬飛;董菊紅;聞國權(quán);;薄芝糖肽對乳腺癌化療患者的免疫增強、減毒作用[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年02期

8 徐美蓮;林志;;薄芝糖肽治療小兒輪狀病毒性腸炎78例臨床觀察[J];海峽藥學(xué);2015年11期

9 夏莉;李樂;高瓊;扈淑英;秦景;尚元元;喻楠;葛新紅;施惠娟;郭靖;楊曉東;;薄芝糖肽局封聯(lián)合他克莫司乳膏治療局限性硬皮病的病理分析[J];寧夏醫(yī)科大學(xué)學(xué)報;2015年10期

10 郝曉菁;趙喜榮;;薄芝糖肽注射液引發(fā)藥物不良反應(yīng)分析[J];臨床合理用藥雜志;2015年28期

【二級參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 沈桂泉;劉勝明;;替比夫定聯(lián)合胸腺肽a1治療慢性乙型肝炎臨床研究[J];醫(yī)藥與保健;2014年02期

2 吳彬;;干擾素、利巴韋林聯(lián)合胸腺五肽治療慢性丙型肝炎療效觀察[J];中國現(xiàn)代藥物應(yīng)用;2013年23期

3 巨煜華;;阿德福韋酯聯(lián)合胸腺五肽治療HBeAg陰性的慢性乙型肝炎療效觀察[J];內(nèi)科;2013年05期

4 于樂成;何長倫;汪茂榮;;HBsAg定量與抗病毒治療關(guān)系的研究進展[J];傳染病信息;2013年04期

5 yそ，

本文編號：2020076